Repligen (RGEN) 10-Q 2 Aug 22 2022 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2022	Jul. 29, 2022
Cover [Abstract]
Amendment Flag	false
Document Type	10-Q
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Central Index Key	0000730272
Current Fiscal Year End Date	--12-31
Document Period End Date	Jun. 30, 2022
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity File Number	000-14656
Entity Registrant Name	REPLIGEN CORP
Entity Filer Category	Large Accelerated Filer
Trading Symbol	RGEN
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2729386
Entity Address, Address Line One	41 Seyon Street, Bldg. 1, Suite 100
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02453
City Area Code	781
Entity Shell Company	false
Smaller reporting company	false
Emerging growth company	false
Local Phone Number	250-0111
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		55,491,199

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 596,512	$ 603,814
Accounts receivable, net of reserves of $1,279 and $1,417 at June 30, 2022 and December 31, 2021, respectively	121,050	117,420
Inventories, net	239,117	184,494
Prepaid expenses and other current assets	19,316	25,949
Total current assets	975,995	931,677
Property, plant and equipment, net	168,370	124,964
Intangible assets, net	322,208	337,274
Goodwill	854,328	860,362
Deferred tax assets	1,907	1,903
Operating lease right of use assets	121,339	101,559
Other noncurrent assets	769	615
Total noncurrent assets	1,468,921	1,426,677
Total assets	2,444,916	2,358,354
Current liabilities:
Accounts payable	40,379	36,203
Operating lease liability	11,692	8,303
Current contingent consideration	17,046	0
Accrued liabilities	70,693	75,498
Convertible Senior Notes, net	283,712	255,258
Total current liabilities	423,522	375,262
Deferred tax liabilities	23,651	33,480
Noncurrent operating lease liability	121,271	102,492
Noncurrent contingent consideration	67,897	94,238
Other noncurrent liabilities	3,211	2,815
Total noncurrent liabilities	216,030	233,025
Total liabilities	639,552	608,287
Commitments and contingencies (Note 9)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.01 par value; 80,000,000 shares authorized; 55,465,918 shares at June 30, 2022 and 55,321,457 shares at December 31, 2021	555	553
Additional paid-in capital	1,533,762	1,572,340
Accumulated other comprehensive loss	(37,091)	(16,886)
Accumulated earnings	308,138	194,060
Total stockholders' equity	1,805,364	1,750,067
Total liabilities and stockholders' equity	$ 2,444,916	$ 2,358,354

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accounts receivable, reserve for doubtful accounts	$ 1,279	$ 1,417
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	55,465,918	55,321,457
Common stock, shares outstanding	55,465,918	55,321,457

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Revenue	$ 207,633	$ 162,960	$ 414,033	$ 305,797
Costs and operating expenses:
Cost of product revenue	86,260	61,990	168,616	121,737
Research and development	10,440	8,389	22,595	16,001
Selling, general and administrative	54,649	44,341	108,949	83,436
Contingent consideration	(6,884)	0	(9,295)	0
Total costs and operating expenses	144,465	114,720	290,865	221,174
Income from operations	63,168	48,240	123,168	84,623
Other income (expenses):
Investment income	708	41	785	93
Interest expense	(271)	(2,787)	(563)	(5,541)
Amortization of debt issuance costs	(453)	(357)	(905)	(709)
Other expenses	(3,396)	(779)	(3,798)	(1,003)
Other expenses, net	(3,412)	(3,882)	(4,481)	(7,160)
Income before income taxes	59,756	44,358	118,687	77,463
Income tax provision	9,895	8,125	21,862	11,780
Net income	$ 49,861	$ 36,233	$ 96,825	$ 65,683
Earnings per share:
Basic	$ 0.90	$ 0.66	$ 1.75	$ 1.20
Diluted (Note 12)	$ 0.88	$ 0.64	$ 1.68	$ 1.16
Weighted average common shares outstanding:
Basic	55,444	54,931	55,399	54,868
Diluted (Note 12)	56,721	56,786	57,842	56,824
Net income	$ 49,861	$ 36,233	$ 96,825	$ 65,683
Other comprehensive income (loss):
Foreign currency translation adjustment	(15,517)	3,125	(20,205)	(6,454)
Comprehensive income	34,344	39,358	76,620	59,229
Products
Revenue:
Revenue	207,597	162,920	413,960	305,657
Royalty and other revenue
Revenue:
Revenue	$ 36	$ 40	$ 73	$ 140

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	True Up Costs December 2020	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital True Up Costs December 2020	Accumulated Other Comprehensive Income (Loss)	Retained Earnings
Translation adjustment	$ (6,454)					$ (6,454)
Balance at Dec. 31, 2020	1,529,150		$ 548	$ 1,460,748		2,085	$ 65,769
Beginning Balance (in shares) at Dec. 31, 2020			54,760,837
Net income	65,683						65,683
Issuance of common stock for debt conversion	1		$ 0	1
Issuance of common stock for debt conversion (in shares)			3
Exercise of stock options and vesting of stock units	860		$ 2	858
Exercise of stock options and vesting of stock units (in shares)			208,641
Stock-based compensation expense	13,684			13,684
True-up of costs related to the December 2020 issuance of common stock		$ 145			$ 145
Balance at Jun. 30, 2021	1,603,069		$ 550	1,475,436		(4,369)	131,452
Ending Balance (in shares) at Jun. 30, 2021			54,969,481
Translation adjustment	3,125					3,125
Balance at Mar. 31, 2021	1,556,216		$ 549	1,467,942		(7,494)	95,219
Beginning Balance (in shares) at Mar. 31, 2021			54,899,245
Net income	36,233						36,233
Exercise of stock options and vesting of stock units	352		$ 1	351
Exercise of stock options and vesting of stock units (in shares)			70,236
Stock-based compensation expense	7,143			7,143
Balance at Jun. 30, 2021	1,603,069		$ 550	1,475,436		(4,369)	131,452
Ending Balance (in shares) at Jun. 30, 2021			54,969,481
Translation adjustment	(20,205)					(20,205)
Balance at Dec. 31, 2021	1,750,067		$ 553	1,572,340		(16,886)	194,060
Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021	(21,817)			(39,070)			17,253
Beginning Balance (in shares) at Dec. 31, 2021			55,321,457
Net income	96,825						96,825
Issuance of common stock for debt conversion	(5)		$ 0	(5)
Issuance of common stock for debt conversion (in shares)			12
Exercise of stock options and vesting of stock units	463		$ 3	460
Exercise of stock options and vesting of stock units (in shares)			222,727
Tax withholding on vesting of restricted stock units	(14,759)		$ (1)	(14,758)
Tax withholding on vesting of restricted stock units (in shares)			(78,278)
Stock-based compensation expense	14,900			14,900
Other	(105)			(105)
Balance at Jun. 30, 2022	1,805,364		$ 555	1,533,762		(37,091)	308,138
Ending Balance (in shares) at Jun. 30, 2022			55,465,918
Translation adjustment	(15,517)					(15,517)
Balance at Mar. 31, 2022	1,766,401		$ 554	1,529,144		(21,574)	258,277
Beginning Balance (in shares) at Mar. 31, 2022			55,429,046
Net income	49,861						49,861
Issuance of common stock for debt conversion	(3)		$ 0	(3)
Issuance of common stock for debt conversion (in shares)			4
Exercise of stock options and vesting of stock units	166		$ 1	166
Exercise of stock options and vesting of stock units (in shares)			51,737
Tax withholding on vesting of restricted stock units	(2,448)		$ 0	(2,448)
Tax withholding on vesting of restricted stock units (in shares)			(14,869)
Stock-based compensation expense	6,985			6,985
Other	(82)			(82)
Balance at Jun. 30, 2022	$ 1,805,364		$ 555	$ 1,533,762		$ (37,091)	$ 308,138
Ending Balance (in shares) at Jun. 30, 2022			55,465,918

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net income	$ 96,825	$ 65,683
Adjustments to reconcile net income to net cash provided by operating activities:
Inventory step-up amortization	0	1,598
Depreciation and amortization	23,933	17,420
Amortization of debt discount and issuance costs	905	5,690
Stock-based compensation expense	14,900	13,684
Deferred income taxes, net	738	5,266
Contingent consideration	(9,295)	0
Other	276	103
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(8,433)	(31,940)
Inventories	(58,106)	(42,773)
Prepaid expenses and other assets	2,402	(563)
Operating lease right of use assets	(21,457)	(3,582)
Other assets	(406)	1,748
Accounts payable	6,322	8,317
Accrued expenses	(4,014)	4,467
Operating Lease Liabilities	23,852	(3,713)
Long-term liabilities	392	(1,655)
Total cash provided by operating activities	68,834	46,913
Cash flows from investing activities:
Acquisitions, net of cash acquired	0	71
Additions to capitalized software costs	(1,875)	(2,191)
Purchases of property, plant and equipment	(52,576)	(24,078)
Other investing activities	17	0
Total cash used in investing activities	(54,434)	(26,198)
Cash flows from financing activities:
Proceeds from exercise of stock options	463	860
Payment of tax withholding obligation on vesting of restricted stock	(14,759)	0
Repayment of Convertible Senior Notes	(18)	(8)
Total cash (used in) provided by financing activities	(14,314)	852
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(7,388)	(4,532)
Net (decrease) increase in cash, cash equivalents and restricted cash	(7,302)	17,035
Cash, cash equivalents and restricted cash, beginning of period	603,814	717,292
Cash and cash equivalents, end of period	596,512	734,327
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	$ 21,739	$ 28,605

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company”, “Repligen”, “our” or “we”) in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 17, 2022 (“Form 10-K”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The business and economic uncertainty resulting from the novel coronavirus pandemic (“COVID-19”), the Russia-Ukraine conflict, supply chain challenges, cost pressure and the overall effects of the current high inflation environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB, Repligen GmbH, Spectrum ® LifeSciences LLC and its subsidiaries (“Spectrum”), C Technologies, Inc., ARTeSYN Biosolutions Holdings Ireland Limited and its subsidiaries, Polymem S.A. (“Polymem”), Avitide LLC, Newton T&M Corp. ("NTM"), Bio-Flex Solutions, L.L.C. ("BioFlex") and Repligen Singapore Pte. Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. Except for the change in the Company's policy on Convertible Senior Notes as required by Accounting Standards Update ("ASU" or "ASUs") 2020-06 and discussed in Note 7, "Convertible Senior Notes," to these consolidated financial statements, the Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. Certain prior year balances have been reclassified to conform to current year presentation. Recent Accounting Standards Updates We consider the applicability and impact of all ASUs on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that we feel may be applicable to the Company are as follows: Recently Issued Accounting Standards Updates – Adopted During the Fiscal Year Effective January 1, 2022, the Company adopted ASU 2020-06, “ Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)” using the modified retrospective method of adoption. ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. Consequently, a convertible instrument is now accounted for as a single liability measured at its amortized cost as long as no other features of such convertible instrument require bifurcation and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments will typically be closer to the coupon interest rate when applying the guidance in Topic 835, “Interest.” The Company now accounts for its 0.375% convertible senior notes due July 15, 2024 (the "2019 Notes") as a single liability measured at amortized cost. As a result, the adoption of ASU 2020-06 had a material impact on the Company's consolidated financial statements, resulting in adjustments of $ 39.1 million, $ 17.3 million and $ 27.6 million to the opening balances of additional paid-in capital, retained earnings and Convertible Senior Notes, net, respectively, on the Company's consolidated balance sheet as of January 1, 2022. Additionally, due to the adoption of ASU 2020-06, the Company reversed the remaining balance of the deferred tax liability of $ 6.4 million, which was initially recorded in connection with the 2019 Notes. See Note 7, “Convertible Senior Notes,” for more information, including our modified disclosures as required by ASU 2020-06 upon adoption. Recently Issued Accounting Standard Updates – Not Yet Adopted In March 2022, the Financial Accounting Standards Board issued ASU 2022-02, “Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures.” ASU 2022-02 eliminates the accounting guidance for Troubled Debt Restructurings by creditors that have adopted ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” while enhancing disclosure requirements for certain loan refinancing and restructurings made to borrowers experiencing financial difficulty. Additionally, ASU 2022-02 adds the requirement for companies to disclose current period write-offs by year of origination for financing receivables. ASU 2022-02 will become effective for the Company on January 1, 2023. Early adoption is permitted if an entity has adopted ASU 2016-13. The Company is currently evaluating the timing and impact of the adoption of ASU 2022-02 on the Company’s consolidated financial statements and disclosures.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Measurements	2. Fair Value Measurements The Company uses various valuation approaches in determining the fair value of its assets and liabilities. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 – Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. Level 3 – Valuations based on inputs that are unobservable and significant to the overall fair value measurement. The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement. Fair Value Measured on a Recurring Basis Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of June 30, 2022 and December 31, 2021 (amounts in thousands): As of June 30, 2022 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 389,374 $ — $ — $ 389,374 Liabilities: Short-term contingent consideration $ — $ — $ 17,046 $ 17,046 Long-term contingent consideration $ — $ — $ 67,897 $ 67,897 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 460,936 $ — $ — $ 460,936 Liabilities: Long-term contingent consideration $ — $ — $ 94,238 $ 94,238 Cash and cash equivalents As of June 30, 2022 and December 31, 2021, cash and cash equivalents on the Company's consolidated balance sheets included $ 389.4 million and $ 460.9 million, respectively, in money market accounts. These funds are valued on a recurring basis using Level 1 inputs. Contingent Consideration – Earnout On September 20, 2021, the Company completed the acquisition of Avitide, Inc. ("Avitide") (the "Avitide Acquisition"), a privately-held affinity ligand discovery and development company headquartered in Lebanon, New Hampshire. The transaction consisted of upfront payments of $ 150.0 million, comprised of cash and the Company's common stock, and up to an additional $ 125.0 million (undiscounted) in contingent consideration for performance-based earnout payments made equally in cash and the Company's common stock over a three-year performance period beginning January 1, 2022 and ending December 31, 2024. See Note 3, "Acquisitions" below for additional information. During 2022, there was a shift in revenue and volume projections, due to the expected timing of achievement over the three-year performance period, and an increase in risk-free interest rates that are used to calculate the discount rate, that resulted in a material change in amounts reported as of June 30, 2022 . A reconciliation of the change in the fair value of contingent consideration - earnout is included in the following table (amounts in thousands): Balance as of December 31, 2021 $ 94,238 Contingent consideration earnouts ( 9,295 ) Balance as of June 30, 2022 $ 84,943 The recurring Level 3 fair value measurement of our contingent consideration earnout that we expect to be required to settle include the following significant unobservable inputs (amounts in thousands, except percent data): Contingent Consideration Earnout Fair Value as of Valuation Technique Unobservable Input Range Weighted Average (1) Probability of Commercialization-based Monte Carlo Success 100 % 100 % payments $ 28,390 Simulation Earnout Discount Rate 4.5 %- 5.8 % 5.1 % Volatility 23.7 % 23.7 % Revenue and Volume- Monte Carlo Revenue & Volume based payments $ 56,553 Simulation Discount Rate 7.4 % 7.4 % Earnout Discount Rate 4.5 %- 5.8 % 5.1 % (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. The Company estimates the fair value of the contingent consideration earnouts at each subsequent reporting period using a Monte Carlo simulation. Changes in the projected performance of the acquired business could result in a higher or lower contingent consideration obligation in the future. Fair Value Measured on a Nonrecurring Basis During the three and six months ended June 30, 2022, there were no re-measurements to fair value of financial assets and liabilities that are measured at fair value on a nonrecurring basis. Convertible Senior Notes In July 2019, the Company issued $ 287.5 million aggregate principal amount of the 2019 Notes. Interest is payable semi-annually in arrears on January 15 and July 15 of each year. The 2019 Notes will mature on July 15, 2024, unless earlier converted or repurchased in accordance with their terms. At June 30, 2022 and December 31, 2021, the carrying value of the 2019 Notes was $ 283.7 million and $ 255.3 million, respectively, net of unamortized discount and issuance costs, and the fair value of the 2019 Notes was $ 432.3 million and $ 678.5 million, respectively. The fair value of the 2019 Notes is a Level 1 valuation and was determined based on the most recent trade activity of the 2019 Notes as of June 30, 2022. The 2019 Notes are discussed in more detail in Note 7, “Convertible Senior Notes” to this report.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisitions	3. Acquisitions 2021 Acquisitions Bio-Flex Solutions L.L.C. and Newton T&M Corp. On November 29, 2021, the Company entered into an Equity Purchase Agreement with BioFlex, NTM and each of Ralph Meola and Jason Nisler (the "Equity Purchase Agreement"), to acquire 100 % of the outstanding securities of BioFlex and NTM (collectively, the “NTM Acquisition”). The transaction closed on December 16, 2021. NTM, which is headquartered in Newton, New Jersey, is the parent company of BioFlex and focuses on manufacturing of products, while BioFlex, also headquartered in Newton, New Jersey, commercializes branded products to biotech customers. The NTM Acquisition complements and expands the Company's filtration offering paths as the industry migrates to single-use flow paths solutions for monoclonal antibody, vaccine and cell and gene therapy ("C&GT") applications, with a focus on single-use fluid management components, including single-use clamps, adapters, end caps and hose assemblies. The NTM Acquisition streamlines and increases control over many components in the Company's single-use supply chain which ultimately should drive reduced lead-times for Repligen customers in the coming years. Consideration Transferred The NTM Acquisition was accounted for as a purchase of businesses under ASC 805, “Business Combinations,” and the Company engaged a third-party valuation firm to assist with the valuation of the business acquired. Under the terms of the Equity Purchase Agreement, all outstanding shares of capital stock of BioFlex were acquired for consideration with a value totaling $ 31.6 million, which includes $ 3.0 million deposited into an escrow against which the Company may make claims for indemnification. Under the acquisition method of accounting, the assets acquired and liabilities assumed of BioFlex were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired is estimated to be $ 4.6 million, the fair value of the intangible assets acquired is estimated to be $ 17.2 million and the residual goodwill is estimated to be $ 9.8 million. The estimated consideration and preliminary purchase price information has been prepared using a preliminary valuation. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company has incurred $ 1.9 million of transaction and integration costs associated with the NTM Acquisition from the date of acquisition to June 30, 2022 , with $ 0.7 million and $ 1.6 million of transaction and integration costs incurred during the three and six months ended June 30, 2022, respectively. The transaction costs are included in operating expenses in the consolidated statements of comprehensive income for the periods ended June 30, 2022. The preparation of the valuation required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results may differ from these estimates. Fair Value of Net Assets Acquired The preliminary allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the preliminary valuation. As of June 30, 2022, the purchase accounting for this acquisition had not yet been finalized. As additional information becomes available, the Company may further revise its preliminary purchase price allocation during the remainder of the measurement period. Any such revisions or changes may have a material impact on our accounting treatment of the NTM Acquisition. The final allocation may include changes to deferred tax assets and other assets and liabilities. The components and estimated allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 2,870 Accounts receivable 1,408 Inventory 741 Prepaid expenses and other current assets 126 Property and equipment 34 Operating lease right of use asset 1,034 Customer relationships 13,240 Developed technology 3,540 Trademark and tradename 310 Non-competition agreements 60 Goodwill 9,804 Long term deferred tax asset 111 Accounts payable ( 224 ) Accrued liabilities ( 450 ) Operating lease liability ( 1,030 ) Operating lease liability, long-term ( 3 ) Fair value of net assets acquired $ 31,571 During the first half of 2022, the Company recorded net working capital adjustments of approximately $ 0.4 million related to pre-acquisition liabilities, which are included in goodwill and accrued liabilities in the table above. Acquired Goodwill The goodwill of $ 9.8 million represents future economic benefits expected to arise from anticipated synergies from the integration of BioFlex and NTM into the Company. These synergies include certain cost savings, operating efficiencies and other strategic benefits projected to be achieved as a result of the NTM Acquisition. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes. Intangible Assets The following table sets forth the components of the identified intangible assets associated with the NTM Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 10 years $ 13,240 Developed technology 11 years 3,540 Trademark and tradename 15 years 310 Non-competition agreements 3 years 60 $ 17,150 Avitide, Inc. On September 16, 2021, the Company entered into an Agreement and Plan of Merger and Reorganization (“Avitide Merger Agreement”) with Avalon Merger Sub, Inc., a Delaware corporation and a wholly owned direct subsidiary of the Company, Avalon Merger Sub LLC, a Delaware limited liability company and a wholly owned direct subsidiary of the Company, Avitide, a Delaware corporation, and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative, agent and attorney-in-fact of Avitide's securityholders to purchase Avitide. The transaction closed on September 20, 2021 on the terms set forth in the Avitide Merger Agreement. Avitide, which is headquartered in Lebanon, New Hampshire, offers diverse libraries and leading technology in affinity ligand discovery and development resulting in best-in-class ligand discovery and development lead-times. The acquisition gives the Company a new platform for affinity resin development, including C&GT, and advances and expands the Company’s proteins and chromatography franchise to address the unique purification needs of gene therapies and other emerging modalities. Consideration Transferred The Avitide Acquisition was accounted for as a purchase of a business under ASC 805, “Business Combinations,” and the Company engaged a third-party valuation firm to assist with the valuation of the business acquired. Under the terms of the Avitide Merger Agreement, all outstanding shares of capital stock of Avitide were cancelled and converted into the right to receive merger consideration with a value totaling up to $ 275.0 million, which consisted of upfront payments in aggregate of $ 150.0 million ($ 149.4 million, net of cash acquired) and up to an additional $ 125.0 million (undiscounted) in contingent consideration earnout payments if certain performance targets are achieved. Total consideration paid also included $ 0.8 million deposited into an escrow account against which the Company may make claims for indemnification. The Avitide Acquisition was funded through payment of $ 75.0 million in cash, the issuance of 271,096 unregistered shares of the Company’s common stock totaling $ 83.0 million and contingent consideration with a fair value of approximately $ 88.4 million. Under the acquisition method of accounting, the assets acquired and liabilities assumed of Avitide were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired is estimated to be $ 2.1 million, the fair value of the intangible assets acquired is estimated to be $ 46.7 million and the residual goodwill is estimated to be $ 197.5 million. The estimated consideration and preliminary purchase price information has been prepared using a preliminary valuation. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company has incurred $ 3.9 million of transaction and integration costs associated with the Avitide Acquisition from the date of acquisition to June 30, 2022, with $ 0.7 million and $ 1.3 million of transaction and integration costs incurred during the three and six months ended June 30, 2022, respectively. The transaction costs are included in operating expenses in the consolidated statements of comprehensive income for the periods ended June 30, 2022. During 2022, due to the change in market inputs used to prepare the valuation of the contingent consideration obligation, the Company also recorded contingent consideration adjustments of ($ 6.9 ) million and ($ 9.3 ) million to the Company's consolidated statements of comprehensive income for the three and six months ended June 30, 2022, respectively. See Note 2, "Fair Value Measurements" for more information. The preparation of the valuation required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results may differ from these estimates. Total consideration transferred is as follows (amounts in thousands): Cash consideration $ 74,962 Equity consideration 82,968 Contingent consideration - earnout 88,373 Fair value of net assets acquired $ 246,303 Fair Value of Net Assets Acquired The preliminary allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the preliminary valuation. As of June 30, 2022, the purchase accounting for this acquisition had not yet been finalized. As additional information becomes available, the Company may further revise its preliminary purchase price allocation during the remainder of the measurement period (which will not exceed 12 months from September 20, 2021). Any such revisions or changes may have a material impact on our accounting treatment of the Avitide Acquisition. The final allocation may include changes to long-term deferred liabilities and goodwill. Upon conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments will be recorded to our consolidated statement of comprehensive income. The components and estimated allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 572 Accounts receivable 228 Inventory 332 Prepaid expenses and other current assets 114 Property and equipment 1,862 Operating lease right of use asset 3,648 Customer relationships 24,580 Developed technology 20,650 Trademark and tradename 1,210 Non-competition agreements 210 Goodwill 197,461 Long term deferred tax asset 1,540 Accounts payable ( 215 ) Accrued liabilities ( 2,183 ) Operating lease liability ( 698 ) Operating lease liability, long-term ( 2,950 ) Other liabilities ( 58 ) Fair value of net assets acquired $ 246,303 Acquired Goodwill The goodwill of $ 197.5 million represents future economic benefits expected to arise from anticipated synergies from the integration of Avitide. These synergies include certain cost savings, operating efficiencies and other strategic benefits projected to be achieved as a result of the Avitide Acquisition. Substantially all of the goodwill recorded is expected to be nondeductible for income tax purposes. In June 2022, the Company recorded an adjustment to goodwill of $ 1.8 million related to a change in estimated tax benefits associated with the net operating loss carryforward filed on the Avitide pre-acquisition tax return. Intangible Assets The following table sets forth the components of the identified intangible assets associated with the Avitide Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 13 years $ 24,580 Developed technology 15 years 20,650 Trademark and tradename 18 years 1,210 Non-competition agreements 3 years 210 $ 46,650 Polymem S.A. On June 22, 2021, the Company entered into a Stock Purchase Agreement with Polymem, a company organized under the laws of France, and Jean-Michel Espenan and Franc Saux, acting together jointly and severally as the representatives of the sellers pursuant to which the Company acquired all of the outstanding common stock of Polymem for $ 47.0 million. The transaction closed on July 1, 2021 (the “Polymem Acquisition”). Polymem, which is headquartered in, Toulouse, France, is a manufacturer of hollow fiber membranes, membrane modules and systems for industrial and bioprocessing applications. Polymem products will complement and expand the Company’s portfolio of hollow fiber systems and consumables. The acquisition substantially increases Repligen’s membrane and module manufacturing capacity and establishes a world-class center of excellence in Europe to address the accelerating global demand for these innovative products. Consideration Transferred The Polymem Acquisition was accounted for as a purchase of a business under ASC 805, “Business Combinations,” and the Company engaged a third-party valuation firm to assist with the valuation of the business acquired. Payment for the transaction was denominated in Euros but is reflected here in U.S. dollars for presentation purposes based on an exchange rate of 0.8437 as of July 1, 2021, the date of acquisition. Total consideration paid was approximately $ 47.0 million, which included approximately $ 4.3 million deposited into an escrow account against which the Company may make claims for indemnification. Under the acquisition method of accounting, the assets acquired and liabilities assumed of Polymem were recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The fair value of the net assets acquired is approximately $ 2.2 million, the fair value of the intangible assets acquired is approximately $ 9.1 million and the residual goodwill is approximately $ 35.7 million. Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which costs are incurred. The Company has incurred $ 6.3 million of transaction and integration costs associated with the Polymem Acquisition from the date of acquisition to June 30, 2022, with $ 1.6 million and $ 3.2 million of transaction and integration costs incurred during the three and six months ended June 30, 2022, respectively. The transaction costs are included in operating expenses in the consolidated statements of comprehensive income for the periods ended June 30, 2022. Fair Value of Net Assets Acquired The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the final valuation of Polymem. The Company has made appropriate adjustments to the purchase price allocation during the measurement period, which ended on July 1, 2022. The components and final allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 353 Net working capital (excluding cash and inventory 414 Inventory step-up 543 Operating lease right of use assets 1,424 Property and equipment 3,145 Other assets 41 Developed technology 8,274 Trademark and tradenames 510 Non-compete agreements 312 Goodwill 35,680 Operating lease liability ( 1,253 ) Long term deferred tax liability ( 2,327 ) Other long-term liabilities ( 143 ) Fair value of net assets acquired $ 46,973 Acquired Goodwill The goodwill of approximately $ 35.7 million represents future economic benefits expected to arise from anticipated synergies from the integration of Polymem. These synergies include certain cost savings, operating efficiencies and other strategic benefits projected to be achieved as a result of the Polymem Acquisition. Substantially all of the goodwill recorded is expected to be nondeductible for income tax purposes. Intangible Assets The following table sets forth the components of the identified intangible assets associated with the Polymem Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Developed technology 13 years $ 8,274 Trademark and tradename 14 years 510 Non-competition agreements 5 years 312 $ 9,096

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Revenue Recognition	4. Revenue Recognition The Company generates revenue from the sale of bioprocessing products, equipment devices and related consumables used with these equipment devices to customers in the life science and biopharmaceutical industries. Under ASC 606, “Revenue from Contracts with Customers,” revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Disaggregation of Revenue Revenues for the three and six months ended June 30, 2022 and 2021 were as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 (Amounts in thousands) Product revenue $ 207,597 $ 162,920 $ 413,960 $ 305,657 Royalty and other income 36 40 73 140 Total revenue $ 207,633 $ 162,960 $ 414,033 $ 305,797 When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because substantially all of its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, regulatory, economic and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. In addition, a significant portion of the Company’s revenue is generated from a small number of customers; therefore, economic factors specific to these customers could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. Disaggregated revenue from contracts with customers by geographic region and revenue from significant customers can be found in Note 14, “Segment Reporting,” included in this report. For more information regarding our product revenue, see Note 6, “Revenue Recognition” included in Part II, Item 8, “ Financial Statements and Supplementary Data” to our Form 10-K. Contract Balances from Contracts with Customers The following table provides information about receivables and deferred revenue from contracts with customers as of June 30, 2022 (amounts in thousands): June 30, December 31, 2022 2021 Balances from contracts with customers only: Accounts receivable $ 121,050 $ 117,420 Deferred revenue (included in accrued liabilities in $ 22,161 $ 14,848 Revenue recognized during periods presented relating to: The beginning deferred revenue balance $ 11,215 $ 13,708 The timing of revenue recognition, billings and cash collections results in the accounts receivable and deferred revenue balances on the Company’s consolidated balance sheets. A contract asset is created when the Company satisfies a performance obligation by transferring a promised good to the customer. Contract assets may represent conditional or unconditional rights to consideration. The right is conditional and recorded as a contract asset if the Company must first satisfy another performance obligation in the contract before it is entitled to payment from the customer. Contract assets are transferred to billed receivables once the right becomes unconditional. If the Company has the unconditional right to receive consideration from the customer, the contract asset is accounted for as a billed receivable and presented separately from other contract assets. A right is unconditional if nothing other than the passage of time is required before payment of that consideration is due. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	5. Goodwill and Intangible Assets Goodwill Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination and determined to have an indefinite useful life is not amortized, but instead is tested for impairment at least annually in accordance with ASC 350, “Intangibles – Goodwill and Other” . The following table represents the change in the carrying value of goodwill for the six months ended June 30, 2022 (amounts in thousands): Balance as of December 31, 2021 $ 860,362 Measurement period adjustment - BioFlex ( 376 ) Measurement period adjustment - Avitide ( 1,784 ) Cumulative translation adjustment ( 3,874 ) Balance as of June 30, 2022 $ 854,328 During each of the fourth quarters of 2021, 2020 and 2019, the Company completed its annual impairment assessments and concluded that goodwill was not impaired in any of those years. The Company has not identified any “triggering” events which indicate an impairment of goodwill in the three and six months ended June 30, 2022. Intangible Assets Intangible assets with a definitive life are amortized over their useful lives using the straight-line method, and the amortization expense is recorded within cost of product revenue and selling, general and administrative expenses in the Company’s statements of comprehensive income. Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions existed that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for the Company's products or changes in the size of the market for the Company’s products. An impairment results if the carrying value of the asset exceeds the estimated fair value of the asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its intangible assets are recoverable at June 30, 2022. Indefinite-lived intangible assets are reviewed for impairment at least annually. There has been no impairment of the Company’s intangible assets for the periods presented. Intangible assets, net consisted of the following at June 30, 2022: June 30, 2022 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 145,304 $ ( 25,862 ) $ 119,442 17 Patents 240 ( 240 ) — 8 Customer relationships 253,221 ( 58,709 ) 194,512 15 Trademarks 7,675 ( 1,096 ) 6,579 19 Other intangibles 2,801 ( 1,826 ) 975 4 Total finite-lived intangible assets 409,241 ( 87,733 ) 321,508 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 409,941 $ ( 87,733 ) $ 322,208 Intangible assets consisted of the following at December 31, 2021: December 31, 2021 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 146,097 $ ( 21,553 ) $ 124,544 17 Patents 240 ( 240 ) — 8 Customer relationships 254,699 ( 50,719 ) 203,980 15 Trademarks 7,699 ( 877 ) 6,822 19 Other intangibles 2,839 ( 1,611 ) 1,228 4 Total finite-lived intangible assets 411,574 ( 75,000 ) 336,574 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 412,274 $ ( 75,000 ) $ 337,274 Amortization expense for finite-lived intangible assets was $ 6.6 million and $ 5.2 million for each of the three months ended June 30, 2022 and 2021, respectively, and $ 13.2 million and $ 10.4 million for each of the six months ended June 30, 2022 and 2021 , respectively. As of June 30, 2022, the Company expects to record the following amortization expense in future periods (amounts in thousands): Estimated Amortization For the Years Ended December 31, Expense 2022 (remaining six months) $ 13,182 2023 26,246 2024 25,661 2025 25,322 2026 25,322 2027 and thereafter 205,775 Total $ 321,508

Consolidated Balance Sheet Deta

Consolidated Balance Sheet Detail	6 Months Ended
	Jun. 30, 2022
Consolidated Balance Sheet Detail	6. Consolidated Balance Sheet Detail Inventories, net Inventories, net consists of the following: June 30, December 31, 2022 2021 (Amounts in thousands) Raw materials $ 141,673 $ 123,321 Work-in-process 7,126 8,119 Finished products 90,318 53,054 Total inventories, net $ 239,117 $ 184,494 Property, Plant and Equipment Property, plant and equipment consist of the following: June 30, December 31, 2022 2021 (Amounts in thousands) Land $ 876 $ 1,023 Buildings 679 764 Leasehold improvements 54,786 52,505 Equipment 75,132 70,983 Furniture, fixtures and office equipment 10,333 9,137 Computer hardware and software 27,655 22,380 Construction in progress 77,807 38,446 Other 504 443 Total property, plant and equipment 247,772 195,681 Less - Accumulated depreciation ( 79,402 ) ( 70,717 ) Total property, plant and equipment, net $ 168,370 $ 124,964 Depreciation expenses totaled $ 5.5 million and $ 3.8 million for each of the three months ended June 30, 2022 and 2021, respectively, and $ 10.7 million and $ 7.0 million for each of the six months ended June 30, 2022 and 2021, respectively. Accrued Liabilities Accrued liabilities consist of the following: June 30, December 31, 2022 2021 (Amounts in thousands) Employee compensation $ 28,232 $ 42,147 Deferred revenue 22,161 14,848 Income taxes payable 4,937 4,984 Other 15,363 13,519 Total accrued liabilities $ 70,693 $ 75,498

Convertible Senior Notes

Convertible Senior Notes	6 Months Ended
	Jun. 30, 2022
Convertible Senior Notes	7. Convertible Senior Notes 0.375% Convertible Senior Notes due 2024 On July 19, 2019, the Company issued $ 287.5 million aggregate principal pursuant to the 2019 Notes, which includes the underwriters’ exercise in full of an option to purchase an additional $ 37.5 million aggregate principal amount of 2019 Notes (the “Notes Offering”). The net proceeds of the Notes Offering, after deducting underwriting discounts and commissions and other related offering expenses payable by the Company, were approximately $ 278.5 million. The 2019 Notes are senior, unsecured obligations of the Company, and bear interest at a rate of 0.375 % per year. Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The 2019 Notes will mature on July 15, 2024 , unless earlier repurchased or converted in accordance with their terms. During the second quarter of 2022, the closing price of the Company’s common stock exceeded 130 % of the conversion price of the 2019 Notes for more than 20 trading days of the last 30 consecutive trading days of the quarter. As a result, the 2019 Notes are convertible at the option of the holders of the 2019 Notes during the third quarter of 2022, the quarter immediately following the quarter when the conditions are met, as stated in the terms of the 2019 Notes. These conditions have been met each quarter since the third quarter of 2020. As a result, $ 24,000 aggregate principal amount of the 2019 Notes have been converted by the note holders since the issuance of the 2019 Notes, including $ 13,000 in the first half of 2022. The conversions resulted in the issuance of a nominal number of shares of the Company’s common stock to the note holders. The Company continues to classify the carrying value of the 2019 Notes as current liabilities on the Company’s consolidated balance sheet at June 30, 2022. Prior to the adoption of ASU 2020-06, the Company accounted for the 2019 Notes as a liability and equity component where the carrying value of the liability component was valued based on a similar debt instrument. In accounting for the issuance of the 2019 Notes, the Company separated the 2019 Notes into liability and equity components. The carrying value of the liability component was calculated as the present value of its cash flows using a discount rate of 4.5 % based on comparative convertible transactions for similar companies. The carrying value of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the 2019 Notes as a whole. The excess of the principal amount of the liability component over its carrying value amount, referred to as the debt discount, was amortized to interest expense on our consolidated statements of comprehensive income over the five-year term of the 2019 Notes. The equity component was not re-measured as long as it continued to meet the conditions for equity classification. The equity component related to the 2019 Notes recorded at issuance was $ 52.1 million, which was recorded in additional paid-in capital on the Company's consolidated balance sheets. In accounting for the transaction costs related to the issuance of the 2019 Notes, the Company allocated the total costs incurred to the liability and equity components of the 2019 Notes using the same proportions as the initial carrying value of the 2019 Notes. Transaction costs related to the liability component were $ 7.4 million and are amortized to interest expense using the effective interest method over the five-year term of the 2019 Notes. Transaction costs attributable to the equity component were $ 1.6 million and are netted with the equity component of the 2019 Notes in stockholders' equity of the Company's consolidated balance sheets. Additionally, the Company recorded a net deferred tax liability of $ 11.4 million. Effective January 1, 2022, the Company adopted ASU 2020-06. After adoption, the Company now accounts for the 2019 Notes as a single liability measured at amortized cost. As the equity component is no longer required to be split into a separate component, the Company recorded a net adjustment for the initial $ 50.4 million that was allocated to additional paid-in capital and $ 22.9 million of life-to-date interest expense recorded as amortization of debt discount. Additionally, the net deferred tax liability recorded for the 2019 Notes was reversed. The principal amount of the liability over its carrying amount is amortized to interest expense over the five-year term of the 2019 Notes. Since the 2019 Notes are classified as a single liability, there is no debt discount required to be amortized for the three and six months ended June 30, 2022. The net carrying value of the liability component of the 2019 Notes is as follows: June 30, December 31, 2022 2021 (Amounts in thousands) 0.375% Convertible Senior Notes due 2024: Principal amount $ 287,476 $ 287,489 Unamortized debt discount — ( 28,220 ) Unamortized debt issuance costs ( 3,764 ) ( 4,011 ) Net carrying amount $ 283,712 $ 255,258 The following table sets forth total interest expense recognized related to the 2019 Notes: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 (Amounts in thousands) Contractual interest expense $ 269 $ 269 $ 539 $ 539 Amortization of debt issuance costs 453 357 905 709 Amortization of debt discount — 2,508 — 4,986 Total $ 722 $ 3,134 $ 1,444 $ 6,234 Effective interest rate of the liability component 1.0 % 5.1 % 1.0 % 5.1 % At June 30, 2022 and December 31, 2021, the carrying value of the 2019 Notes was $ 283.7 million and $ 255.3 million, respectively, net of unamortized discount, and the fair value of the 2019 Notes was $ 432.3 million and $ 678.5 million, respectively. The fair value of the 2019 Notes was determined based on the most recent trade activity of the 2019 Notes at June 30, 2022 and December 31, 2021.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity	8. Stockholders’ Equity Stock Option and Incentive Plans Under the Company’s current 2018 Stock Option and Incentive Plan (the “2018 Plan”), the number of shares of the Company’s common stock that are reserved and available for issuance is 2,778,000 , plus the number of shares of common stock available for issuance under the Company’s previous equity plans. The shares of common stock underlying any awards under the 2018 Plan and previous equity plans (together, the “Plans”) that are forfeited, canceled or otherwise terminated (other than by exercise) shall be added back to the shares of stock available for issuance under the 2018 Plan. At June 30, 2022, 1,948,381 shares were available for future grants under the 2018 Plan. Stock-Based Compensation For each of the three months ended June 30, 2022 and 2021, the Company recorded stock-based compensation expense of $ 7.0 million and $ 7.1 million, respectively, for share-based awards granted under the Plans. For the six months ended June 30, 2022 and 2021, the Company recorded stock-based compensation expense of $ 14.9 million and $ 13.7 million, respectively. The following table presents stock-based compensation expense in the Company’s consolidated statements of comprehensive income: Three Months Ended Six Months Ended 2022 2021 2022 2021 (Amounts in thousands) Cost of product revenue $ 615 $ 449 $ 1,237 $ 955 Research and development 622 795 1,421 1,511 Selling, general and administrative 5,748 5,899 12,242 11,218 Total stock-based compensation $ 6,985 $ 7,143 $ 14,900 $ 13,684 The 2018 Plan allows for the granting of incentive and nonqualified options to purchase shares of common stock, restricted stock and other equity awards. Employee grants under the Plans generally vest over a three to five-year period, with 20 %- 33 % vesting on the first anniversary of the date of grant and the remainder vesting in equal yearly installments thereafter. Nonqualified options issued to non-employee directors under the Plans generally vest over one year. In the first quarter of 2018, to create a longer-term retention incentive, the Company’s Compensation Committee granted long-term incentive compensation awards to its Chief Executive Officer, which consisted of both stock options and restricted stock units (“RSUs”) that are subject to time-based vesting over nine years . Options granted under the Plans have a maximum term of ten years from the date of grant and generally, the exercise price of the stock options equals the fair market value of the Company’s common stock on the date of grant. At June 30, 2022, options to purchase 648,546 shares and 551,029 stock units were outstanding under the Plans. Stock Options The Company uses the Black-Scholes option pricing model to calculate the fair value of stock option awards on the grant date, and the Company uses the value of the common stock as of the grant date to value RSUs. The Company measures stock-based compensation costs for stock options at the grant date based on the estimated fair value of the award. The Company recognizes expense on awards with service-based vesting over the employee’s requisite service period on a straight-line basis. The Company recognizes stock-based compensation expense for options that are ultimately expected to vest, and accordingly, such compensation expense has been adjusted for estimated forfeitures. Information regarding option activity for the six months ended June 30, 2022 under the Plans is summarized below: Shares Weighted Weighted- Aggregate Options outstanding at December 31, 2021 625,107 $ 54.15 6.29 $ 131,707 Granted 47,838 $ 180.82 Exercised ( 16,399 ) $ 28.20 Forfeited/expired/cancelled ( 8,000 ) $ 193.86 Options outstanding at June 30, 2022 648,546 $ 62.42 6.09 $ 67,377 Options exercisable at June 30, 2022 381,399 $ 46.21 5.49 $ 44,750 Vested and expected to vest at June 30, 2022 (1) 632,147 6.08 $ 65,687 (1) Represents the number of vested options as of June 30, 2022 plus the number of unvested options expected to vest as of June 30, 2022 based on the unvested outstanding options at June 30, 2022 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (the difference between the closing price of the common stock on June 30, 2022, the last business day of the second quarter of 2022, of $ 162.40 per share and the exercise price of each in-the-money option) that would have been received by the option holders had all option holders exercised their options on June 30, 2022. The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2022 and 2021 was $ 2.4 million and $ 6.0 million, respectively. The weighted average grant date fair value of options granted during the six months ended June 30, 2022 and 2021 was $ 76.64 and $ 86.96 , respectively. The total fair value of stock options that vested during the six months ended June 30, 2022 and 2021 was $ 2.7 million and $ 2.5 million, respectively. Stock Units The fair value of stock units is calculated using the closing price of the Company’s common stock on the date of grant. The Company recognizes expense on awards with service-based vesting over the employee’s requisite service period on a straight-line basis. The Company recognizes expense on performance-based awards over the vesting period based on the probability that the performance metrics will be achieved. Information regarding stock unit activity, which includes activity for RSUs and performance stock units, for the six months ended June 30, 2022 under the Plans is summarized below: Shares Weighted- Aggregate Unvested at December 31, 2021 606,685 3.07 $ 160,674 Awarded 144,845 Vested ( 175,647 ) Forfeited/expired/cancelled ( 24,854 ) Unvested at June 30, 2022 551,029 3.00 $ 89,487 Vested and expected to vest at June 30, 2022 (1) 535,061 2.63 $ 86,894 (1) Represents the number of vested stock units as of June 30, 2022 plus the number of unvested stock units expected to vest as of June 30, 2022 based on the unvested outstanding stock units at June 30, 2022 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees. The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value (equal to the closing price of the common stock on June 30, 2022, the last business day of the second quarter of 2022, of $ 162.40 per share, as stock units do not have an exercise price) that would have been received by the stock unit holders had all holders exercised on June 30, 2022. The aggregate intrinsic value of stock units vested during the six months ended June 30, 2022 and 2021 was $ 37.5 million and $ 35.8 million, respectively. The weighted average grant date fair value of stock units granted during the six months ended June 30, 2022 and 2021 was $ 191.09 and $ 206.15 , respectively. The total fair value of stock units that vested during the six months ended June 30, 2022 and 2021 was $ 17.9 million and $ 9.6 million, respectively. As of June 30, 2022, there was $ 70.4 million of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 3.01 years. The Company expects 1,790,901 unvested options and stock units to vest over the next five years .

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies	9. Commitments and Contingencies In June 2018, the Company secured an agreement with Navigo Proteins GmbH (“Navigo”) for the exclusive co-development of multiple affinity ligands for which the Company holds commercialization rights. The Company is manufacturing and supplying the first of these ligands, NGL-Impact ® , exclusively to Purolite Life Sciences, an Ecolab Inc. company (“Purolite”), who is pairing the Company’s high-performance ligand with Purolite’s agarose jetting base bead technology used in their Jetted A50 Protein A resin product. The Company also signed a long-term supply agreement with Purolite for NGL-Impact and other potential additional affinity ligands that may advance from the Company’s Navigo collaboration. In September 2020, the Company and Navigo successfully completed co-development of an affinity ligand targeting the SARS-CoV-2 spike protein, to be utilized in the purification of COVID-19 vaccines. The Company has proceeded with scaling up and manufacturing this ligand and the development and validation of the related affinity chromatography resin, which is marketed by the Company. In September 2021, the Company and Navigo successfully completed co-development of a novel affinity ligand that addresses aggregation issues associated with pH sensitive antibodies and Fc-fusion proteins. The Company is manufacturing and supplying this ligand, NGL-Impact ® HipH, to Purolite for use in a platform use resin product. The Navigo and Purolite agreements are supportive of the Company’s strategy to secure and reinforce the Company’s proteins business. The Company made royalty payments to Navigo of $ 0.7 million and $ 0.3 million for the three months ended June 30, 2022 and 2021, respectively and payments of $ 1.1 million and $ 0.6 million for the six months ended June 30, 2022 and 2021, respectively.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2022
Accumulated Other Comprehensive Loss	10. Accumulated Other Comprehensive Loss The following shows the changes in the components of accumulated other comprehensive loss for the six months ended June 30, 2022 which consisted of only foreign currency translation adjustments for the periods shown (amounts in thousands): Foreign Currency Translation Adjustment Balance at December 31, 2021 $ ( 16,886 ) Other comprehensive loss ( 20,205 ) Balance at June 30, 2022 $ ( 37,091 )

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Taxes	11. Income Taxes For the three and six months ended June 30, 2022 , we recorded an income tax provision of $ 9.9 million and $ 21.9 million, respectively. The Company’s effective tax rate for the three and six months ended June 30, 2022 was 16.6 % and 18.4 %, respectively, compared to 18.3 % and 15.2 % for the corresponding periods in the prior year. The difference in effective tax rates between the periods was primarily due to higher income before income taxes, lower windfall benefits recognized on stock option exercises and the vesting of stock units partially offset by lower U.S. taxation of foreign earnings. The effective tax rates for the three and six months ended June 30, 2022 and 2021 were lower than the U.S. statutory rate of 21 % primarily due to business tax credits and windfall benefits on stock option exercises and the vesting of stock units.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share	12. Earnings Per Share The Company reports earnings per share (“EPS”) in accordance with ASC 260, “Earnings Per Share,” which establishes standards for computing and presenting EPS. Basic EPS is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS is computed by dividing net income available to common shareholders by the weighted-average number of common shares and dilutive common share equivalents then outstanding. Potential common share equivalents consist of RSUs, performance stock units and the incremental common shares issuable upon the exercise of stock options. In periods when the Company has a net loss, stock awards are excluded from the calculation of EPS as their inclusion would have an antidilutive effect. A reconciliation of basic and diluted weighted average shares outstanding is as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 (Amounts in thousands, except per share data) Numerator: Net income $ 49,861 $ 36,233 $ 96,825 $ 65,683 Effect of dilutive securities: Charges associated with convertible debt instruments, net of tax — — 387 — Numerator for diluted earnings per share - net income available to common stockholders after the effect of dilutive securities $ 49,861 $ 36,233 $ 97,212 $ 65,683 Denominator: Weighted average shares used in computing net income per share - basic 55,444 54,931 55,399 54,868 Effect of dilutive shares: Options and stock units 598 843 661 903 Convertible Senior Notes 676 1,012 1,779 1,052 Dilutive effect of unvested performance stock units 3 — 3 — Dilutive potential common shares 1,277 1,855 2,443 1,956 Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted 56,721 56,786 57,842 56,824 Earnings per share: Basic $ 0.90 $ 0.66 $ 1.75 $ 1.20 Diluted $ 0.88 $ 0.64 $ 1.68 $ 1.16 At June 30, 2022, there were outstanding options to purchase 648,546 shares of the Company’s common stock at a weighted average exercise price of $ 62.42 per share and 551,029 shares of common stock issuable upon the vesting of stock units, which include RSUs and performance stock units. For the three and six months ended June 30, 2022, 325,685 shares and 306,400 shares, respectively, of the Company’s common stock were excluded from the calculation of diluted EPS because the exercise prices of the stock options were greater than or equal to the average price of the common shares and were therefore anti-dilutive. At June 30, 2021, there were outstanding options to purchase 682,913 shares of the Company’s common stock at a weighted average exercise price of $5 1.71 per share and 618,618 shares of common stock issuable upon the vesting of stock units, which include RSUs and performance stock units. For the three and six months ended June 30, 2021, 69,388 shares of the Company’s common stock were excluded from the calculation of diluted EPS because the exercise prices of the stock options were greater than or equal to the average price of the common shares and were therefore anti-dilutive. In July 2019, the Company issued $ 287.5 million aggregate principal amount of the 2019 Notes. As provided by the terms of the indenture underlying the 2019 Notes, prior to March 4, 2022, conversion of the 2019 Notes could have been settled in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. On March 4, 2022, we entered into the Second Supplemental Indenture for the 2019 Notes, which irrevocably elected to settle the conversion of the 2019 Notes using a combination of cash and shares of the Company’s common stock, settling the par value of the 2019 Notes in cash and any excess conversion premium in shares. As provided by the terms of the Second Supplemental Indenture underlying the 2019 Notes, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company's common stock. This means the Company will settle the par value of the 2019 Notes in cash and any excess conversion premium in shares. As mentioned in Note 7, "Convertible Senior Notes," the Company adopted ASU 2020-06 effective January 1, 2022. Under ASU 2020-06, the Company is required to reflect the dilutive effect of the convertible securities by application of the "if-converted" method, which means the denominator of the EPS calculation would include the total number of shares assuming the 2019 Notes had been fully converted at the beginning of the period. Prior to March 4, 2022, the Company had the choice to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 (the date the Company adopted ASU 2020-06) to March 4, 2022, the Company included 3,474,429 shares in the denominator of the EPS calculation, applying the if converted method. Subsequent to March 4, 2022, after the Second Supplemental Indenture became effective, the Company irrevocably elected to settle the conversion obligation for the 2019 Notes in a combination of cash and shares of the Company's common stock, and from March 5, 2022 forward, only the excess premium will be settled with shares. Under the if-converted method of calculating dilutive shares, the Company was also required to exclude amortization of debt issuance costs and interest charges applicable to the convertible debt from the numerator of the dilutive EPS calculation for the period from January 1, 2022 to March 4, 2022, as if the interest on convertible debt was never recognized for that period. For the six months ended June 30, 2022 , the Company excluded interest charges of $ 0.4 million (net of tax) from the numerator. Prior to the adoption of ASU 2020-06, the Company applied the provisions of ASC 260, “Earnings Per Share,” Subsection 10-45-44, to determine the diluted weighted average shares outstanding as it related to the conversion spread on its convertible notes. Accordingly, the par value of the 2019 Notes was not included in the calculation of diluted income per share, but the dilutive effect of the conversion premium was considered in the calculation of diluted net income per share using the treasury stock method. The dilutive impact of the 2019 Notes was based on the difference between the Company’s current period average stock price and the conversion price of the 2019 Notes, provided there was a premium. Pursuant to this accounting standard, there was no dilution from the accreted principal of the 2019 Notes. For the three and six months ended June 30, 2022, the dilutive effect of the conversion premium included in the calculation of diluted earnings was 676,166 shares and 1,779,041 shares, respectively. For the three and six months ended June 30, 2021, the dilutive effect of the conversion premium included in the calculation of diluted earnings was 1,011,993 shares and 1,052,337 shares, respectively.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions	13. Related Party Transactions Certain facilities leased by Spectrum are owned by the Roy T. Eddleman Living Trust (the "Trust"). As of June 30, 2022 , the Trust owned greater than 5 % of the Company’s outstanding shares. Therefore, the Company considers the Trust to be a related party. The lease amounts paid to the Trust prior to the public offering were negotiated in connection with the acquisition of Spectrum. The Company incurred rent expense totaling $ 0.2 million for each of the three months ended June 30, 2022 and 2021 related to these leases and incurred rent expense of $ 0.4 million for each of the six months ended June 30, 2022 and 2021 .

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Reporting	14. Segment Reporting The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company. The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Revenue by customers' geographic locations: North America 45 % 41 % 43 % 42 % Europe 35 % 40 % 39 % 39 % APAC/Other 20 % 19 % 18 % 19 % Total revenue 100 % 100 % 100 % 100 % Concentrations of Credit Risk and Significant Customers Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. Treasury obligations) and type of instrument is limited. At June 30, 2022 and December 31, 2021, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements. Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential write-off of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition. There was no revenue from customers that represented 10 % or more of the Company's total revenue for the three and six months ended June 30, 2022 and 2021. No accounts receivable balance from a specific customer represented 10 % or more of the Company's total trade accounts receivable at June 30, 2022. Significant accounts receivable balances representing 10 % or more of the Company’s total trade accounts receivable and royalties at December 31, 2021 came from our accounts receivable balance outstanding with Pfizer Inc., which was 14 % of our total accounts receivable and other receivable balance.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Basis of presentation	Basis of Presentation The consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company”, “Repligen”, “our” or “we”) in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, which was filed with the SEC on February 17, 2022 (“Form 10-K”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The business and economic uncertainty resulting from the novel coronavirus pandemic (“COVID-19”), the Russia-Ukraine conflict, supply chain challenges, cost pressure and the overall effects of the current high inflation environment on customers' purchasing patterns has made such estimates more difficult to calculate. Accordingly, actual results could differ from those estimates. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB, Repligen GmbH, Spectrum ® LifeSciences LLC and its subsidiaries (“Spectrum”), C Technologies, Inc., ARTeSYN Biosolutions Holdings Ireland Limited and its subsidiaries, Polymem S.A. (“Polymem”), Avitide LLC, Newton T&M Corp. ("NTM"), Bio-Flex Solutions, L.L.C. ("BioFlex") and Repligen Singapore Pte. Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. Except for the change in the Company's policy on Convertible Senior Notes as required by Accounting Standards Update ("ASU" or "ASUs") 2020-06 and discussed in Note 7, "Convertible Senior Notes," to these consolidated financial statements, the Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year. Certain prior year balances have been reclassified to conform to current year presentation.
Recent Accounting Standards Updates	Recent Accounting Standards Updates We consider the applicability and impact of all ASUs on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued ASUs that we feel may be applicable to the Company are as follows: Recently Issued Accounting Standards Updates – Adopted During the Fiscal Year Effective January 1, 2022, the Company adopted ASU 2020-06, “ Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)” using the modified retrospective method of adoption. ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. Consequently, a convertible instrument is now accounted for as a single liability measured at its amortized cost as long as no other features of such convertible instrument require bifurcation and recognition as derivatives. By removing those separation models, the interest rate of convertible debt instruments will typically be closer to the coupon interest rate when applying the guidance in Topic 835, “Interest.” The Company now accounts for its 0.375% convertible senior notes due July 15, 2024 (the "2019 Notes") as a single liability measured at amortized cost. As a result, the adoption of ASU 2020-06 had a material impact on the Company's consolidated financial statements, resulting in adjustments of $ 39.1 million, $ 17.3 million and $ 27.6 million to the opening balances of additional paid-in capital, retained earnings and Convertible Senior Notes, net, respectively, on the Company's consolidated balance sheet as of January 1, 2022. Additionally, due to the adoption of ASU 2020-06, the Company reversed the remaining balance of the deferred tax liability of $ 6.4 million, which was initially recorded in connection with the 2019 Notes. See Note 7, “Convertible Senior Notes,” for more information, including our modified disclosures as required by ASU 2020-06 upon adoption. Recently Issued Accounting Standard Updates – Not Yet Adopted In March 2022, the Financial Accounting Standards Board issued ASU 2022-02, “Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures.” ASU 2022-02 eliminates the accounting guidance for Troubled Debt Restructurings by creditors that have adopted ASU 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” while enhancing disclosure requirements for certain loan refinancing and restructurings made to borrowers experiencing financial difficulty. Additionally, ASU 2022-02 adds the requirement for companies to disclose current period write-offs by year of origination for financing receivables. ASU 2022-02 will become effective for the Company on January 1, 2023. Early adoption is permitted if an entity has adopted ASU 2016-13. The Company is currently evaluating the timing and impact of the adoption of ASU 2022-02 on the Company’s consolidated financial statements and disclosures.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of June 30, 2022 and December 31, 2021 (amounts in thousands): As of June 30, 2022 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 389,374 $ — $ — $ 389,374 Liabilities: Short-term contingent consideration $ — $ — $ 17,046 $ 17,046 Long-term contingent consideration $ — $ — $ 67,897 $ 67,897 As of December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market accounts $ 460,936 $ — $ — $ 460,936 Liabilities: Long-term contingent consideration $ — $ — $ 94,238 $ 94,238
Schedule of Reconciliation of the Change in the Fair Value of Contingent Consideration - Earnout	A reconciliation of the change in the fair value of contingent consideration - earnout is included in the following table (amounts in thousands): Balance as of December 31, 2021 $ 94,238 Contingent consideration earnouts ( 9,295 ) Balance as of June 30, 2022 $ 84,943
Schedule of Contingent Consideration Earnout Expect to be Required to Settle Include Significant Unobservable Inputs	The recurring Level 3 fair value measurement of our contingent consideration earnout that we expect to be required to settle include the following significant unobservable inputs (amounts in thousands, except percent data): Contingent Consideration Earnout Fair Value as of Valuation Technique Unobservable Input Range Weighted Average (1) Probability of Commercialization-based Monte Carlo Success 100 % 100 % payments $ 28,390 Simulation Earnout Discount Rate 4.5 %- 5.8 % 5.1 % Volatility 23.7 % 23.7 % Revenue and Volume- Monte Carlo Revenue & Volume based payments $ 56,553 Simulation Discount Rate 7.4 % 7.4 % Earnout Discount Rate 4.5 %- 5.8 % 5.1 % Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2022
BioFlex And NTM Acquisition
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The components and estimated allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 2,870 Accounts receivable 1,408 Inventory 741 Prepaid expenses and other current assets 126 Property and equipment 34 Operating lease right of use asset 1,034 Customer relationships 13,240 Developed technology 3,540 Trademark and tradename 310 Non-competition agreements 60 Goodwill 9,804 Long term deferred tax asset 111 Accounts payable ( 224 ) Accrued liabilities ( 450 ) Operating lease liability ( 1,030 ) Operating lease liability, long-term ( 3 ) Fair value of net assets acquired $ 31,571
Schedule of Identified Intangible Assets and Estimated Useful Lives	The following table sets forth the components of the identified intangible assets associated with the NTM Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 10 years $ 13,240 Developed technology 11 years 3,540 Trademark and tradename 15 years 310 Non-competition agreements 3 years 60 $ 17,150
Avitide, Inc.
Schedule of Business Combination Consideration Transferred	Total consideration transferred is as follows (amounts in thousands): Cash consideration $ 74,962 Equity consideration 82,968 Contingent consideration - earnout 88,373 Fair value of net assets acquired $ 246,303
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The components and estimated allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 572 Accounts receivable 228 Inventory 332 Prepaid expenses and other current assets 114 Property and equipment 1,862 Operating lease right of use asset 3,648 Customer relationships 24,580 Developed technology 20,650 Trademark and tradename 1,210 Non-competition agreements 210 Goodwill 197,461 Long term deferred tax asset 1,540 Accounts payable ( 215 ) Accrued liabilities ( 2,183 ) Operating lease liability ( 698 ) Operating lease liability, long-term ( 2,950 ) Other liabilities ( 58 ) Fair value of net assets acquired $ 246,303
Schedule of Identified Intangible Assets and Estimated Useful Lives	The following table sets forth the components of the identified intangible assets associated with the Avitide Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Customer relationships 13 years $ 24,580 Developed technology 15 years 20,650 Trademark and tradename 18 years 1,210 Non-competition agreements 3 years 210 $ 46,650
Polymem S.A.
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The components and final allocation of the purchase price consist of the following (amounts in thousands): Cash and cash equivalents $ 353 Net working capital (excluding cash and inventory 414 Inventory step-up 543 Operating lease right of use assets 1,424 Property and equipment 3,145 Other assets 41 Developed technology 8,274 Trademark and tradenames 510 Non-compete agreements 312 Goodwill 35,680 Operating lease liability ( 1,253 ) Long term deferred tax liability ( 2,327 ) Other long-term liabilities ( 143 ) Fair value of net assets acquired $ 46,973
Schedule of Identified Intangible Assets and Estimated Useful Lives	The following table sets forth the components of the identified intangible assets associated with the Polymem Acquisition and their estimated useful lives: Useful life Fair Value (Amounts in thousands) Developed technology 13 years $ 8,274 Trademark and tradename 14 years 510 Non-competition agreements 5 years 312 $ 9,096

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Disaggregation of Revenue	Revenues for the three and six months ended June 30, 2022 and 2021 were as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 (Amounts in thousands) Product revenue $ 207,597 $ 162,920 $ 413,960 $ 305,657 Royalty and other income 36 40 73 140 Total revenue $ 207,633 $ 162,960 $ 414,033 $ 305,797
Summary of Receivables and Deferred Revenue from Contracts with Customers	The following table provides information about receivables and deferred revenue from contracts with customers as of June 30, 2022 (amounts in thousands): June 30, December 31, 2022 2021 Balances from contracts with customers only: Accounts receivable $ 121,050 $ 117,420 Deferred revenue (included in accrued liabilities in $ 22,161 $ 14,848 Revenue recognized during periods presented relating to: The beginning deferred revenue balance $ 11,215 $ 13,708

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Changes in Carrying Value of Goodwill	The following table represents the change in the carrying value of goodwill for the six months ended June 30, 2022 (amounts in thousands): Balance as of December 31, 2021 $ 860,362 Measurement period adjustment - BioFlex ( 376 ) Measurement period adjustment - Avitide ( 1,784 ) Cumulative translation adjustment ( 3,874 ) Balance as of June 30, 2022 $ 854,328
Intangible assets	Intangible assets, net consisted of the following at June 30, 2022: June 30, 2022 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 145,304 $ ( 25,862 ) $ 119,442 17 Patents 240 ( 240 ) — 8 Customer relationships 253,221 ( 58,709 ) 194,512 15 Trademarks 7,675 ( 1,096 ) 6,579 19 Other intangibles 2,801 ( 1,826 ) 975 4 Total finite-lived intangible assets 409,241 ( 87,733 ) 321,508 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 409,941 $ ( 87,733 ) $ 322,208 Intangible assets consisted of the following at December 31, 2021: December 31, 2021 Gross Accumulated Net Weighted (Amounts in thousands) Finite-lived intangible assets: Technology - developed $ 146,097 $ ( 21,553 ) $ 124,544 17 Patents 240 ( 240 ) — 8 Customer relationships 254,699 ( 50,719 ) 203,980 15 Trademarks 7,699 ( 877 ) 6,822 19 Other intangibles 2,839 ( 1,611 ) 1,228 4 Total finite-lived intangible assets 411,574 ( 75,000 ) 336,574 16 Indefinite-lived intangible asset: Trademarks 700 — 700 — Total intangible assets $ 412,274 $ ( 75,000 ) $ 337,274
Schedule of Amortization Expense for Amortized Intangible Assets	As of June 30, 2022, the Company expects to record the following amortization expense in future periods (amounts in thousands): Estimated Amortization For the Years Ended December 31, Expense 2022 (remaining six months) $ 13,182 2023 26,246 2024 25,661 2025 25,322 2026 25,322 2027 and thereafter 205,775 Total $ 321,508

Consolidated Balance Sheet De_2

Consolidated Balance Sheet Detail (Tables)	6 Months Ended
	Jun. 30, 2022
Inventories	Inventories, net Inventories, net consists of the following: June 30, December 31, 2022 2021 (Amounts in thousands) Raw materials $ 141,673 $ 123,321 Work-in-process 7,126 8,119 Finished products 90,318 53,054 Total inventories, net $ 239,117 $ 184,494
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment consist of the following: June 30, December 31, 2022 2021 (Amounts in thousands) Land $ 876 $ 1,023 Buildings 679 764 Leasehold improvements 54,786 52,505 Equipment 75,132 70,983 Furniture, fixtures and office equipment 10,333 9,137 Computer hardware and software 27,655 22,380 Construction in progress 77,807 38,446 Other 504 443 Total property, plant and equipment 247,772 195,681 Less - Accumulated depreciation ( 79,402 ) ( 70,717 ) Total property, plant and equipment, net $ 168,370 $ 124,964
Accrued Liabilities	Accrued Liabilities Accrued liabilities consist of the following: June 30, December 31, 2022 2021 (Amounts in thousands) Employee compensation $ 28,232 $ 42,147 Deferred revenue 22,161 14,848 Income taxes payable 4,937 4,984 Other 15,363 13,519 Total accrued liabilities $ 70,693 $ 75,498

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	6 Months Ended
	Jun. 30, 2022
Carrying Value of Convertible Senior Notes	The net carrying value of the liability component of the 2019 Notes is as follows: June 30, December 31, 2022 2021 (Amounts in thousands) 0.375% Convertible Senior Notes due 2024: Principal amount $ 287,476 $ 287,489 Unamortized debt discount — ( 28,220 ) Unamortized debt issuance costs ( 3,764 ) ( 4,011 ) Net carrying amount $ 283,712 $ 255,258
Schedule of convertiable note interest expense	The following table sets forth total interest expense recognized related to the 2019 Notes: Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 (Amounts in thousands) Contractual interest expense $ 269 $ 269 $ 539 $ 539 Amortization of debt issuance costs 453 357 905 709 Amortization of debt discount — 2,508 — 4,986 Total $ 722 $ 3,134 $ 1,444 $ 6,234 Effective interest rate of the liability component 1.0 % 5.1 % 1.0 % 5.1 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Stock-Based Compensation Expense	The following table presents stock-based compensation expense in the Company’s consolidated statements of comprehensive income: Three Months Ended Six Months Ended 2022 2021 2022 2021 (Amounts in thousands) Cost of product revenue $ 615 $ 449 $ 1,237 $ 955 Research and development 622 795 1,421 1,511 Selling, general and administrative 5,748 5,899 12,242 11,218 Total stock-based compensation $ 6,985 $ 7,143 $ 14,900 $ 13,684
Summary of Option Activity	Information regarding option activity for the six months ended June 30, 2022 under the Plans is summarized below: Shares Weighted Weighted- Aggregate Options outstanding at December 31, 2021 625,107 $ 54.15 6.29 $ 131,707 Granted 47,838 $ 180.82 Exercised ( 16,399 ) $ 28.20 Forfeited/expired/cancelled ( 8,000 ) $ 193.86 Options outstanding at June 30, 2022 648,546 $ 62.42 6.09 $ 67,377 Options exercisable at June 30, 2022 381,399 $ 46.21 5.49 $ 44,750 Vested and expected to vest at June 30, 2022 (1) 632,147 6.08 $ 65,687 (1) Represents the number of vested options as of June 30, 2022 plus the number of unvested options expected to vest as of June 30, 2022 based on the unvested outstanding options at June 30, 2022 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.
Summary of Restricted Stock Unit Activity	Information regarding stock unit activity, which includes activity for RSUs and performance stock units, for the six months ended June 30, 2022 under the Plans is summarized below: Shares Weighted- Aggregate Unvested at December 31, 2021 606,685 3.07 $ 160,674 Awarded 144,845 Vested ( 175,647 ) Forfeited/expired/cancelled ( 24,854 ) Unvested at June 30, 2022 551,029 3.00 $ 89,487 Vested and expected to vest at June 30, 2022 (1) 535,061 2.63 $ 86,894 Represents the number of vested stock units as of June 30, 2022 plus the number of unvested stock units expected to vest as of June 30, 2022 based on the unvested outstanding stock units at June 30, 2022 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Changes in Accumulated Other Comprehensive Loss	The following shows the changes in the components of accumulated other comprehensive loss for the six months ended June 30, 2022 which consisted of only foreign currency translation adjustments for the periods shown (amounts in thousands): Foreign Currency Translation Adjustment Balance at December 31, 2021 $ ( 16,886 ) Other comprehensive loss ( 20,205 ) Balance at June 30, 2022 $ ( 37,091 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Basic and Diluted Weighted Average Shares Outstanding	A reconciliation of basic and diluted weighted average shares outstanding is as follows: Three Months Ended Six Months Ended 2022 2021 2022 2021 (Amounts in thousands, except per share data) Numerator: Net income $ 49,861 $ 36,233 $ 96,825 $ 65,683 Effect of dilutive securities: Charges associated with convertible debt instruments, net of tax — — 387 — Numerator for diluted earnings per share - net income available to common stockholders after the effect of dilutive securities $ 49,861 $ 36,233 $ 97,212 $ 65,683 Denominator: Weighted average shares used in computing net income per share - basic 55,444 54,931 55,399 54,868 Effect of dilutive shares: Options and stock units 598 843 661 903 Convertible Senior Notes 676 1,012 1,779 1,052 Dilutive effect of unvested performance stock units 3 — 3 — Dilutive potential common shares 1,277 1,855 2,443 1,956 Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted 56,721 56,786 57,842 56,824 Earnings per share: Basic $ 0.90 $ 0.66 $ 1.75 $ 1.20 Diluted $ 0.88 $ 0.64 $ 1.68 $ 1.16

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2022
Percentage by Geographic Area or Significant Customers	The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Revenue by customers' geographic locations: North America 45 % 41 % 43 % 42 % Europe 35 % 40 % 39 % 39 % APAC/Other 20 % 19 % 18 % 19 % Total revenue 100 % 100 % 100 % 100 %

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Jan. 01, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Deferred Tax Liabilities		$ 6,400
Additional Paid in Capital		39,100
Accumulated earnings	$ 308,138	17,300	$ 194,060
Convertible Notes Payable, Current	$ 283,712	$ 27,600	$ 255,258

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial assets and financial liabilities measured at fair value on a recurring basis (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term contingent consideration	$ 17,046
Long-term contingent consideration	67,897	$ 94,238
Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	389,374	460,936
Level 1 | Money Market
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	389,374	460,936
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term contingent consideration	17,046
Long-term contingent consideration	$ 67,897	$ 94,238

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($) $ in Thousands			6 Months Ended
	Sep. 20, 2021	Sep. 16, 2021	Jun. 30, 2022	Dec. 31, 2021	Jul. 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents			$ 596,512	$ 603,814
Performance period			3 years
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents			$ 389,400	460,900
0.375% Convertible Senior Notes due 2024
Summary Of Significant Accounting Policies [Line Items]
Principal amount					$ 287,500
Notes, frequency of periodic payment			semi-annually
Total convertible senior notes			$ 283,700	255,300
Fair value of convertible senior notes			432,300	$ 678,500
Avitide, Inc.
Summary Of Significant Accounting Policies [Line Items]
Upfront payment	$ 150,000	$ 75,000
Business combination contingent consideration		$ 88,400	$ 88,373
Additional undiscounted in contingent consideration earnout payments	$ 125,000

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Reconciliation of the Change in the Fair Value of Contingent Consideration - Earnout (Detail) - Contingent Consideration $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance as of December 31, 2021	$ 94,238
Contingent consideration earnouts	9,295
Balance as of June 30 , 2022	$ 84,943

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Contingent Consideration Earnout Expect to be Required to Settle Include Significant Unobservable Inputs (Detail) - Contingent Consideration - USD ($) $ in Thousands		Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 84,943	$ 94,238
Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Probability of success		100%
R&D and Commercialization-based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 28,390
R&D and Commercialization-based Payments | Monte Carlo Simulation | Fair Value, Recurring | Probability of Success
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	100%
R&D and Commercialization-based Payments | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	5.10%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities, fair value		$ 56,553
Volatility		23.70%
Revenue and volume discount rate		7.40%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Earnout Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	5.10%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	23.70%
Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring | Revenue & Volume Discount Rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted average discount rate	[1]	7.40%
Minimum | R&D and Commercialization-based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		4.50%
Minimum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		4.50%
Maximum | R&D and Commercialization-based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		5.80%
Maximum | Revenue and Volume Based Payments | Monte Carlo Simulation | Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Discount Rate		5.80%
[1] Unobservable inputs were weighted by the relative fair value of the contingent consideration liability.

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands					3 Months Ended			6 Months Ended
	Nov. 29, 2021	Sep. 20, 2021	Sep. 16, 2021	Jun. 22, 2021	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired								$ 0	$ (71)
Goodwill					$ 854,328			854,328		$ 860,362
Transaction costs					1,600			1,600
Contingent consideration					(6,884)		$ 0	(9,295)	$ 0
BioFlex And NTM Acquisition
Business Acquisition [Line Items]
Value of common stock issued	$ 31,600
Working capital adjustment								400
Fair value of acquired finite lived intangible assets	17,200
Goodwill					9,804			9,804
Intangible Asset Residual Value	9,800
Transaction costs	$ 1,900				700			700
Business acquisition, voting interest acquired	100%
Business acquisition, Indemnification escrow	$ 3,000
Net asset acquired	4,600
Business combination, intangible assets	$ 17,200
Avitide, Inc.
Business Acquisition [Line Items]
Cash consideration		$ 150,000	$ 75,000
Shares issued for business acquisition			271,096
Value of common stock issued			$ 83,000					82,968
Working capital adjustment								1,800
Net liabilities assumed			2,100
Business combination, consideration transferred								246,303
Fair value of acquired finite lived intangible assets			46,700
Goodwill					197,461			197,461
Intangible Asset Residual Value			197,500
Transaction costs					3,900			3,900
Transaction costs					700			1,300
Contingent consideration						$ 6,900		9,300
Business combination, intangible assets			46,700
Business combination contingent consideration			88,400					88,373
Avitide, Inc. | Capital Stock
Business Acquisition [Line Items]
Cash consideration			150,000
Payments to Acquire Businesses, Net of Cash Acquired			149,400
Business combination, consideration transferred			275,000
Business acquisition, Indemnification escrow			800
Business combination contingent consideration			$ 125,000
Polymem S.A.
Business Acquisition [Line Items]
Cash consideration				$ 47,000
Net liabilities assumed					2,200			2,200
Business combination, consideration transferred								47,000
Fair value of acquired finite lived intangible assets					9,100			9,100
Goodwill					35,680			35,680
Intangible Asset Residual Value					35,700			35,700
Transaction costs					6,300			6,300
Transaction costs					1,600			3,200
Business acquisition, Indemnification escrow								4,300
Business combination, intangible assets					$ 9,100			$ 9,100

Acquisitions - Consideration Tr

Acquisitions - Consideration Transferred (Detail) - Avitide, Inc. - USD ($) $ in Thousands		6 Months Ended
	Sep. 16, 2021	Jun. 30, 2022
Business Acquisition [Line Items]
Cash consideration		$ 74,962
Equity consideration	$ 83,000	82,968
Contingent consideration earnouts	$ 88,400	88,373
Fair value of net assets acquired		$ 246,303

Acquisitions - Fair Value of Ne

Acquisitions - Fair Value of Net Assets Acquired (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Nov. 29, 2021	Sep. 16, 2021
Business Acquisition [Line Items]
Goodwill	$ 854,328	$ 860,362
BioFlex And NTM Acquisition
Business Acquisition [Line Items]
Cash and cash equivalents	2,870
Accounts receivable	1,408
Inventory	741
Prepaid expenses and other current assets	126
Property and equipment	34
Operating lease right of use asset	1,034
Business combination, intangible assets			$ 17,200
Goodwill	9,804
Long term deferred tax asset	111
Accounts payable	(224)
Accrued liabilities	450
Operating lease liability	1,030
Operating lease liability, long-term	3
Fair value of net assets acquired	31,571
BioFlex And NTM Acquisition | Customer relationships
Business Acquisition [Line Items]
Business combination, intangible assets	13,240
BioFlex And NTM Acquisition | Developed technology
Business Acquisition [Line Items]
Business combination, intangible assets	3,540
BioFlex And NTM Acquisition | Trademark and tradename
Business Acquisition [Line Items]
Business combination, intangible assets	310
BioFlex And NTM Acquisition | Non-competition agreements
Business Acquisition [Line Items]
Business combination, intangible assets	60
Avitide, Inc.
Business Acquisition [Line Items]
Cash and cash equivalents	572
Accounts receivable	228
Inventory	332
Prepaid expenses and other current assets	114
Property and equipment	1,862
Operating lease right of use asset	3,648
Business combination, intangible assets				$ 46,700
Goodwill	197,461
Long term deferred tax asset	1,540
Net liabilities assumed				$ 2,100
Accounts payable	(215)
Accrued liabilities	2,183
Operating lease liability	698
Operating lease liability, long-term	2,950
Other liabilities	58
Fair value of net assets acquired	246,303
Avitide, Inc. | Customer relationships
Business Acquisition [Line Items]
Business combination, intangible assets	24,580
Avitide, Inc. | Developed technology
Business Acquisition [Line Items]
Business combination, intangible assets	20,650
Avitide, Inc. | Trademark and tradename
Business Acquisition [Line Items]
Business combination, intangible assets	1,210
Avitide, Inc. | Non-competition agreements
Business Acquisition [Line Items]
Business combination, intangible assets	210
Polymem S.A.
Business Acquisition [Line Items]
Cash and cash equivalents	353
Net working capital (excluding cash and inventory step-up)	414
Inventory	543
Property and equipment	3,145
Operating lease right of use asset	1,424
Other assets	41
Business combination, intangible assets	9,100
Goodwill	35,680
Net liabilities assumed	2,200
Operating lease liability	1,253
Long term deferred tax liability	2,327
Other liabilities	143
Fair value of net assets acquired	46,973
Polymem S.A. | Developed technology
Business Acquisition [Line Items]
Business combination, intangible assets	8,274
Polymem S.A. | Trademark and tradename
Business Acquisition [Line Items]
Business combination, intangible assets	510
Polymem S.A. | Non-competition agreements
Business Acquisition [Line Items]
Business combination, intangible assets	$ 312

Acquisitions - Estimated Useful

Acquisitions - Estimated Useful Life and Fair Value (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
BioFlex And NTM Acquisition
Fair Value	$ 17,150
Avitide, Inc.
Fair Value	46,650
Polymem S.A.
Fair Value	$ 9,096
Customer Relationships [Member] | BioFlex And NTM Acquisition
Weighted Average Useful Life (in years)	10 years
Fair Value	$ 13,240
Customer Relationships [Member] | Avitide, Inc.
Weighted Average Useful Life (in years)	13 years
Fair Value	$ 24,580
Developed Technology Rights [Member] | BioFlex And NTM Acquisition
Weighted Average Useful Life (in years)	11 years
Fair Value	$ 3,540
Developed Technology Rights [Member] | Avitide, Inc.
Weighted Average Useful Life (in years)	15 years
Fair Value	$ 20,650
Developed Technology Rights [Member] | Polymem S.A.
Weighted Average Useful Life (in years)	13 years
Fair Value	$ 8,274
Trademark and tradename [Member] | BioFlex And NTM Acquisition
Weighted Average Useful Life (in years)	15 years
Fair Value	$ 310
Trademark and tradename [Member] | Avitide, Inc.
Weighted Average Useful Life (in years)	18 years
Fair Value	$ 1,210
Trademark and tradename [Member] | Polymem S.A.
Weighted Average Useful Life (in years)	14 years
Fair Value	$ 510
Noncompete Agreements [Member] | BioFlex And NTM Acquisition
Weighted Average Useful Life (in years)	3 years
Fair Value	$ 60
Noncompete Agreements [Member] | Avitide, Inc.
Weighted Average Useful Life (in years)	3 years
Fair Value	$ 210
Noncompete Agreements [Member] | Polymem S.A.
Weighted Average Useful Life (in years)	5 years
Fair Value	$ 312

Revenue Recognition - Summary o

Revenue Recognition - Summary of Disaggregation of Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Total revenue	$ 207,633	$ 162,960	$ 414,033	$ 305,797
Product Revenue
Disaggregation of Revenue [Line Items]
Total revenue	207,597	162,920	413,960	305,657
Royalty and Other Income
Disaggregation of Revenue [Line Items]
Total revenue	$ 36	$ 40	$ 73	$ 140

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Balances from contracts with customers only:
Accounts receivable	$ 121,050	$ 117,420
Deferred revenue (included in accrued liabilities in the consolidated balance sheets)	22,161	14,848
Revenue recognized during periods presented relating to:
The beginning deferred revenue balance	$ 11,215	$ 13,708

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Changes in Carrying Value of Goodwill (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Goodwill [Line Items]
Balance	$ 860,362
Cumulative translation adjustment	(3,874)
Balance	854,328
BioFlex
Goodwill [Line Items]
Measurement period adjustments	(376)
Avitide, Inc.
Goodwill [Line Items]
Measurement period adjustments	(1,784)
Balance	$ 197,461

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Intangible Assets [Line Items]
Gross Carrying Value	$ 409,241	$ 411,574
Gross Carrying Value	409,941	412,274
Accumulated Amortization	(87,733)	(75,000)
Accumulated Amortization	(87,733)	(75,000)
Net Carrying Value	321,508	336,574
Net Carrying Value	$ 322,208	$ 337,274
Weighted Average Useful Life (in years)	16 years	16 years
Trademark
Intangible Assets [Line Items]
Gross Carrying Value	$ 700	$ 700
Net Carrying Value	700	700
Technology - developed
Intangible Assets [Line Items]
Gross Carrying Value	145,304	146,097
Accumulated Amortization	(25,862)	(21,553)
Net Carrying Value	$ 119,442	$ 124,544
Weighted Average Useful Life (in years)	17 years	17 years
Patents
Intangible Assets [Line Items]
Gross Carrying Value	$ 240	$ 240
Accumulated Amortization	(240)	(240)
Net Carrying Value	$ 0	$ 0
Weighted Average Useful Life (in years)	8 years	8 years
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Value	$ 253,221	$ 254,699
Accumulated Amortization	(58,709)	(50,719)
Net Carrying Value	$ 194,512	$ 203,980
Weighted Average Useful Life (in years)	15 years	15 years
Trademarks
Intangible Assets [Line Items]
Gross Carrying Value	$ 7,675	$ 7,699
Accumulated Amortization	(1,096)	(877)
Net Carrying Value	$ 6,579	$ 6,822
Weighted Average Useful Life (in years)	19 years	19 years
Other intangibles
Intangible Assets [Line Items]
Gross Carrying Value	$ 2,801	$ 2,839
Accumulated Amortization	(1,826)	(1,611)
Net Carrying Value	$ 975	$ 1,228
Weighted Average Useful Life (in years)	4 years	4 years

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Finite-Lived Intangible Liabilities [Line Items]
Amortization expense	$ 6.6	$ 5.2	$ 13.2	$ 10.4
Impairment of intangible assets			$ 0

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Amortization Expense for Amortized Intangible Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Liabilities [Line Items]
2022 (remaining six months)	$ 13,182
2023	26,246
2024	25,661
2025	25,322
2026	25,322
2027 and thereafter	205,775
Total	$ 321,508	$ 336,574

Consolidated Balance Sheet De_3

Consolidated Balance Sheet Detail - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Inventory [Line Items]
Raw materials	$ 141,673	$ 123,321
Work-in-process	7,126	8,119
Finished products	90,318	53,054
Total inventories, net	$ 239,117	$ 184,494

Consolidated Balance Sheet De_4

Consolidated Balance Sheet Detail - Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Land	$ 876	$ 1,023
Buildings	679	764
Leasehold improvements	54,786	52,505
Equipment	75,132	70,983
Furniture, fixtures and office equipment	10,333	9,137
Computer hardware and software	27,655	22,380
Construction in progress	77,807	38,446
Other	504	443
Total property, plant and equipment	247,772	195,681
Less - Accumulated depreciation	(79,402)	(70,717)
Total property, plant and equipment, net	$ 168,370	$ 124,964

Consolidated Balance Sheet De_5

Consolidated Balance Sheet Detail - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Depreciation	$ 5.5	$ 3.8	$ 10.7	$ 7

Consolidated Balance Sheet De_6

Consolidated Balance Sheet Detail - Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule of Accrued Liabilities [Line Items]
Employee compensation	$ 28,232	$ 42,147
Deferred revenue	22,161	14,848
Income taxes payable	4,937	4,984
Other	15,363	13,519
Total accrued liabilities	$ 70,693	$ 75,498

Convertible Senior Notes - Addi

Convertible Senior Notes - Additional Information (Detail) $ in Thousands		3 Months Ended		6 Months Ended
	Jul. 19, 2019 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) Days	Jun. 30, 2021 USD ($)	Jan. 01, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 31, 2019 USD ($)
Debt Instrument [Line Items]
Contractual interest expense		$ 269	$ 269	$ 539	$ 539
Amortization of debt discount				905	5,690
Amortization of the debt issuance costs		$ 453	$ 357	$ 905	$ 709
Effective interest rate of the liability component		1%	5.10%	1%	5.10%
Debt Instrument, Convertible, Threshold Trading Days | Days				20
Debt Instrument, Convertible, Threshold Consecutive Trading Days | Days				30
Deferred Tax Liabilities						$ 6,400
Additional paid-in capital		$ 1,533,762		$ 1,533,762			$ 1,572,340
Repayment of convertible debt				18	$ 8
0.375% Convertible Senior Notes due 2024
Debt Instrument [Line Items]
Notes issued		$ 287,500		$ 287,500				$ 287,500
Notes, interest rate		0.375%		0.375%
Proceeds from issuance of convertible senior notes, net of costs	$ 278,500
Interest repayment terms				Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020.
Notes, due date				Jul. 15, 2024
Amortization of debt discount				$ 22,900
Notes, carrying value		$ 283,712		283,712			255,258
Fair value of the note		432,300		432,300			$ 678,500
Additional Notes issued		37,500		$ 37,500
Discount Rate				4.50%
Debt instrument amount convertible into equity		24,000		$ 24,000
Loss on conversion of debt included in other expenses				$ 13,000
Notes threshold percentage of stock price trigger				130%
Convertible Notes Transaction Costs Of Liability Component				$ 7,400
Convertible Notes Transaction Costs Of Equity Component		1,600		1,600
Deferred Tax Liabilities		11,400		11,400
Additional paid-in capital		$ 52,100		52,100
Net adjustment for the initial				$ 50,400

Convertible Senior Notes - Conv

Convertible Senior Notes - Convertible Debt (Detail) - 0.375% Convertible Senior Notes due 2024 - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal amount	$ 287,476	$ 287,489
Unamortized debt discount	0	(28,220)
Unamortized debt issuance costs	(3,764)	(4,011)
Total convertible senior notes	$ 283,712	$ 255,258

Convertible Senior Notes - Sche

Convertible Senior Notes - Schedule of convertiable note interest expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Debt Disclosure [Abstract]
Contractual interest expense	$ 269	$ 269	$ 539	$ 539
Amortization of Debt Issuance Costs	453	357	905	709
Amortization of debt discount	0	2,508	0	4,986
Total	$ 722	$ 3,134	$ 1,444	$ 6,234
Debt Instrument, Interest Rate, Effective Percentage	1%	5.10%	1%	5.10%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense	$ 6,985	$ 7,143	$ 14,900	$ 13,684
Incentive options, term			10 years
Stock options, outstanding	648,546	682,913	648,546	682,913	625,107
Restricted stock units, outstanding	551,029		551,029		606,685
Aggregate intrinsic value of stock options exercised			$ 2,400	$ 6,000
Weighted average grant date fair value of share-based awards granted			$ 76.64	$ 86.96
Total fair value of stock options vested			$ 2,700	$ 2,500
Total unrecognized compensation cost	$ 70,400		$ 70,400
Unrecognized compensation cost, weighted average remaining requisite service period			3 years 3 days
Number of unvested options and restricted stock units	1,790,901		1,790,901
2018 Plan
Stockholders Equity Note Disclosure [Line Items]
Common stock shares reserved for Issuance						2,778,000
Incentive options, vesting period	1,948,381		1,948,381
Employee Stock Option | Minimum
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period			3 years
Employee Stock Option | Minimum | Vest Over Three Year
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting percentage			20%
Employee Stock Option | Maximum
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period			5 years
Employee Stock Option | Maximum | Vest Over Three Year
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting percentage			33%
Non-Employee Directors
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period			9 years
Unvested Options
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period			5 years
Restricted Stock Units and Performance Stock Units
Stockholders Equity Note Disclosure [Line Items]
Restricted stock units, outstanding	551,029	618,618	551,029	618,618
Closing price of common stock	$ 162.40		$ 162.40
Aggregate intrinsic value of restricted stock units vested			$ 37,500	$ 35,800
Weighted average grant date fair value of restricted stock units granted			$ 191.09	$ 206.15
Total grant date fair value of restricted stock units vested			$ 17,900	$ 9,600
RestrictedStockUnitsRSUMember
Stockholders Equity Note Disclosure [Line Items]
Closing price of common stock	$ 162.40		$ 162.40

Stock-Based Compensation Expens

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 6,985	$ 7,143	$ 14,900	$ 13,684
Cost of product revenue
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	615	449	1,237	955
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	622	795	1,421	1,511
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 5,748	$ 5,899	$ 12,242	$ 11,218

Summary of Option Activity (Det

Summary of Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended	12 Months Ended
		Jun. 30, 2022	Dec. 31, 2021
Options Outstanding
Options outstanding at December 31, 2021| shares		625,107
Granted | shares		47,838
Exercised | shares		(16,399)
Forfeited/expired/cancelled		(8,000)
Options outstanding at June 30, 2022 | shares		648,546	625,107
Options exercisable at June 30, 2022 | shares		381,399
Vested and expected to vest at June 30, 2022 (1) | shares	[1]	632,147
Weighted-Average Exercise Price Per Share
Options outstanding at December 31, 2021		$ 54.15
Granted		180.82
Exercised		28.20
Forfeited/expired/cancelled		193.86
Options outstanding at June 30, 2022		62.42	$ 54.15
Options exercisable at June 30, 2022		$ 46.21
Weighted-Average Remaining Contractual Term (in years)
Options outstanding		6 years 1 month 2 days	6 years 3 months 14 days
Options exercisable at June 30, 2022		5 years 5 months 26 days
Vested and expected to vest at June 30, 2022	[1]	6 years 29 days
Aggregate Intrinsic Value
Options outstanding		$ 67,377	$ 131,707
Options exercisable at March 31, 2022		44,750
Vested and expected to vest at March 31, 2022	[1]	$ 65,687
[1] Represents the number of vested options as of June 30, 2022 plus the number of unvested options expected to vest as of June 30, 2022 based on the unvested outstanding options at June 30, 2022 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Summary of Option Activity (Par

Summary of Option Activity (Parenthetical) (Detail) - Employee Stock Option	Jun. 30, 2022
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3%

Summary of Restricted Stock Uni

Summary of Restricted Stock Unit Activity (Detail) - USD ($) $ in Thousands		6 Months Ended	12 Months Ended
		Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Options Outstanding
Unvested at December 31, 2021		606,685
Awarded		144,845
Vested		(175,647)
Forfeited/expired/cancelled		(24,854)
Restricted stock units, outstanding		551,029	606,685
Vested and expected to vest at March 31, 2022	[1]	535,061
Weighted-Average Remaining Contractual Term (in years)
Unvested at December 31, 2021		3 years	3 years 25 days
Vested and expected to vest at March 31, 2022	[1]	2 years 7 months 17 days
Aggregate Intrinsic Value
Unvested at March 31, 2022		$ 89,487	$ 160,674
Vested and expected to vest at March 31, 2022	[1]	$ 86,894
Restricted Stock Units and Performance Stock Units
Options Outstanding
Restricted stock units, outstanding		551,029		618,618
[1] Represents the number of vested stock units as of June 30, 2022 plus the number of unvested stock units expected to vest as of June 30, 2022 based on the unvested outstanding stock units at June 30, 2022 adjusted for estimated forfeiture rates of 8 % for awards granted to non-executive level employees and 3 % for awards granted to executive level employees.

Summary of Restricted Stock U_2

Summary of Restricted Stock Unit Activity (Parenthetical) (Detail) - Restricted Stock Units and Performance Stock Units	Jun. 30, 2022
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
NGL Impact A [Member] | Research and Development Arrangement [Member]
Commitments and Contingencies [Line Items]
Payments to Navigo in connection with this program, which are recorded to research and development expenses	$ 0.7	$ 0.3	$ 1.1	$ 0.6

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Change in Accumulated Other Comprehensive Loss (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 1,750,067
Balance	1,805,364
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(16,886)
Other comprehensive loss	(20,205)
Balance	$ (37,091)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Taxes [Line Items]
Corporate tax rate	21%	21%	21%	21%
Income tax (benefit) provision	16.60%	18.30%	18.40%	15.20%
Income tax provision	$ 9,895	$ 8,125	$ 21,862	$ 11,780

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Mar. 04, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Jul. 31, 2019
Stock options, outstanding		648,546	682,913	648,546	682,913	625,107
Stock options, weighted average exercise price		$ 62.42	$ 1.71	$ 62.42	$ 1.71	$ 54.15
Restricted stock units, outstanding		551,029		551,029		606,685
Common stock excluded from calculation of diluted earnings per share		325,685	69,388	306,400	69,388
Dilutive effect on shares of conversion premium		676,166	1,011,993	1,779,041	1,052,337
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted		56,721	56,786	57,842	56,824
Charges associated with convertible debt instruments, net of tax		$ 0	$ 0	$ 387	$ 0
AccountingStandardsUpdate202006Member
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted	3,474,429
Charges associated with convertible debt instruments, net of tax				400
0.375% Convertible Senior Notes due 2024
Principal amount		$ 287,500		$ 287,500			$ 287,500
Restricted Stock Units and Performance Stock Units
Restricted stock units, outstanding		551,029	618,618	551,029	618,618

Earnings Per Share - Reconcilia

Earnings Per Share - Reconciliation of Basic and Diluted Shares Amounts (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator
Net income	$ 49,861	$ 36,233	$ 96,825	$ 65,683
Effect of dilutive securities
Charges associated with convertible debt instruments, net of tax	0	0	387	0
Numerator for diluted earnings per share - net income available to common stockholders after the effect of dilutive securities	$ 49,861	$ 36,233	$ 97,212	$ 65,683
Denominator
Weighted average shares used in computing net income per share - basic	55,444	54,931	55,399	54,868
Effect of dilutive shares
Options and stock units	598	843	661	903
Convertible senior notes	676	1,012	1,779	1,052
Dilutive effect of unvested performance stock units	3	0	3	0
Dilutive potential common shares	1,277	1,855	2,443	1,956
Denominator for diluted earnings per share - adjusted weighted average shares used in computing net income per share - diluted	56,721	56,786	57,842	56,824
Earnings per share:
Basic	$ 0.90	$ 0.66	$ 1.75	$ 1.20
Diluted (Note 12)	$ 0.88	$ 0.64	$ 1.68	$ 1.16

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Principal Owner - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Related Party Transaction [Line Items]
Spectrum Acquisition, tax preparation and other fees	$ 0.2	$ 0.2	$ 0.4	$ 0.4
Minimum | Spectrum Inc.
Related Party Transaction [Line Items]
Non controlling ownership interest minimum	5%		5%

Segment Reporting - Additional

Segment Reporting - Additional Information (Detail)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) Segment	Jun. 30, 2021 USD ($)	Dec. 31, 2021
Number of operating segments | Segment			1
Accounts receivable, percentage by customer	100%	100%	100%	100%
Revenue	$ 207,633,000	$ 162,960,000	$ 414,033,000	$ 305,797,000
Sales Revenue
Revenue	$ 0	$ 0	$ 0	$ 0
Customer Concentration Risk | Sales Revenue | Minimum [Member]
Accounts receivable, percentage by customer	10%	10%	10%	10%
Customer Concentration Risk | Accounts Receivable [Member] | Pfizer [Member]
Accounts receivable, percentage by customer					14%
Customer Concentration Risk | Accounts Receivable [Member] | Customer Number One [Member]
Accounts receivable, percentage by customer			10%
Customer Concentration Risk | Total Trade Accounts Receivable Royalties And Other Receivables | Pfizer [Member]
Accounts receivable, percentage by customer					10%

Segment Reporting - Percentage

Segment Reporting - Percentage of Revenue by Geographic Area (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Concentration Risk [Line Items]
Revenues, percentage by country	100%	100%	100%	100%
Geographic Concentration Risk | Total Revenue | North America
Concentration Risk [Line Items]
Revenues, percentage by country	45%	41%	43%	42%
Geographic Concentration Risk | Total Revenue | Europe
Concentration Risk [Line Items]
Revenues, percentage by country	35%	40%	39%	39%
Geographic Concentration Risk | Total Revenue | APAC/Other
Concentration Risk [Line Items]
Revenues, percentage by country	20%	19%	18%	19%